跳至主要内容
临床试验/CTIS2022-500107-50-00
CTIS2022-500107-50-00招募中1 期

Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy - CARP

niversity Of Leipzig0 个研究点目标入组 258 人开始时间: 2022年5月3日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
258

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Hilar cholangiocarcinoma (cytological or histological confirmation), Surgery is not planned, Age 18 or older, Written informed consent

排除标准

  • Tumour not accessible endoscopically, Planned surgical procedure within the next 30 days, Concurrent eye disease that will require a slit lamp examination within the next 30 days, Prior radiotherapy within the last four weeks, Previous PDT or RFA, Planned liver transplantation, Known hypersensitivity to porphyrins or to any of the other ingredients of the photosensitizer chosen, Leukopenia (< 2000/mm³), Thrombocytopenia (< 100,000/mm³), Severe, uncorrected coagulopathy (at the discretion of the physician), Suspected erosion of major blood vessels, because of the risk of life-threatening mass haemorrhage exists, Porphyria (clinician’s assessment) or other light-exacerbated diseases, Severely impaired liver and or kidney function (at the discretion of the physician), Bedridden for more than 50% of the time (similar to ECOG grade 3)

研究者

发起方
niversity Of Leipzig

相似试验